• 1
    Kanis JA, Gluer CC 2000 An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192202.
  • 2
    Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:12271233.
  • 3
    Ravaud P, Reny JL, Giraudeau B, Porcher R, Dougados M, Roux C 1999 Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res 14:14491456.
  • 4
    Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W 1992 Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 7:633638.
  • 5
    Hui SL, Slemenda CW, Johnston CC Jr 1989 Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 111:355361.
  • 6
    Delmas PD 2000 How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27:13.
  • 7
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281289.
  • 8
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:110.
  • 9
    Li Z, Meredith MP, Hoseyni MS 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:31753188.
  • 10
    Genant HK, Engelke K, Fuerst T, Gluer CC, Grampp S, Harris ST, Jergas M, Lang T, Lu Y, Majumdar S, Mathur A, Takada M 1996 Noninvasive assessment of bone mineral and structure: State of the art. J Bone Miner Res 11:707730.
  • 11
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J 2000 The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2S17.
  • 12
    Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH 2000 Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11:467480.
  • 13
    Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cornier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 11:15311538.
  • 14
    van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, Birkenhager JC, Pols HA 1996 Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study. BMJ 312:482483.
  • 15
    Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA 2000 Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study. Osteoporos Int 11:7682.
  • 16
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:15261536.
  • 17
    Bjarnason NH, Christiansen C 2000 Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 26:561569.
  • 18
    Delmas PD, Hardy P, Garnero P, Dain M 2000 Monitoring individual response to hormone replacement therapy with bone markers. Bone 26:553560.
  • 19
    Hannon R, Blumsohn A, Naylor K, Eastell R 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. J Bone Miner Res 13:11241133.
  • 20
    Garnero P, Delmas PD 1999 Variability and response of urinary resorption markers to hormone replacement therapy. J Bone Miner Res 14:470472.
  • 21
    Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922930.
  • 22
    Braga de Castro MA, Hannon R, Eastell R 1999 Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 14:602608.
  • 23
    Ravn P, Clemmesen B, Christiansen C 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237244.
  • 24
    Garnero P, Darte C, Delmas PD 1999 A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 24:603609.
  • 25
    Eastell R, Blumsohn A 1997 The value of biochemical markers of bone turnover in osteoporosis. J Rheumatol 24:12151217.
  • 26
    Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB 1999 Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom 2:323342.
  • 27
    Riggs BL 2000 Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients? Bone 26:551552.
  • 28
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:10511056.
  • 29
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott SM, Schneider DL, Thompson D, Orloff J, Ewing S, Delmas PD 2002 Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: The Fracture Intervention Trial. Osteoporos Int 13(Suppl 1):S521.
  • 30
    Delmas PD 2000 Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11(Suppl 6):S66S76.
  • 31
    Melton LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL 1997 Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:10831091.
  • 32
    Johnell O, Scheele WH, Lu Y, Reginster J-Y, Need AG, Seeman E 2002 Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodelling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985992.
  • 33
    Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:36093617.
  • 34
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282:637645.
  • 35
    Genant HK, Jergas M, Palermo L, Nevitt M, San Valentin R, Black D, Cummings SR 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984996.
  • 36
    Lu Y, Mathur AK, Blunt BA, Gluer CC, Will AS, Fuerst TP, Jergas MD, Andriano KN, Cummings SR, Genant HK 1996 Dual X-ray absorptiometry quality control: Comparison of visual examination and process-control charts. J Bone Miner Res 11:626637.
  • 37
    Lu Y, Ye K, Mathur AK, Hui S, Fuerst TP, Genant HK 1997 Comparative calibration without a gold standard. Stat Med 16:18891905.
  • 38
    Unnebrink K, Windeler J 2001 Intention-to-treat: Methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 20:39313946.
  • 39
    Efron B, Stein C 1981 The jackknife estimate of variance. Ann Stat 9:586596.
  • 40
    Freedman LS, Graubard BI, Schatzkin A 1992 Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167178.
  • 41
    Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR 2000 Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 160:7785.
  • 42
    Watts N, Bockman R, Smith C, Li Z, Eastell R, Pack S, Lindsay RB 2000 BMD changes explains only a fraction of the observed fracture risk reduction in risedronate-treated patients. Osteoporos Int 11:S203.
  • 43
    Seeman E 2002 Pathogenesis of bone fragility in women and men. Lancet 359:18411850.
  • 44
    Boivin G, Meunie PJ 2001 Changes in bone remodeling rate influence the degree of mineralization of bone which is a determinant of bone strength: Therapeutic implications. Adv Exp Med Biol 496:123127.
  • 45
    Stepan JJ, Michalska D, Zikan V, Vokrouhlicka J 2002 Biochemical markers of Type I collagen synthesis and degradation in monitoring osteoporosis treatment with raloxifene and alendronate. J Bone Miner Res 17:S1;S233.
  • 46
    Boivin G, Lips P, Ott SM, Harper KD, Sarkar S, Pinette KV, Meunier PJ 2003 Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88:41994205.